The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
TRX/EUDA can literally buy the lot for 10p and make a killing over at EUDA medium term. We will not go bust yet as our spend is relatively low and if it did drop more they can easily put an offer in as we got valuable compounds that are hard to find plus if they really want 201 it will save them money.
I just think it was stupid decision to put the person behind most of the action onto the BOD when he depends on the remaining members especially if they think they are next. Bit of a cat and mouse game but could have been dealt with much better.
Might as well look to sell the company to EUDA given where we are with all this.
That is the problem. He has no knowledge or understanding on a scientific level so he depends on the remaining BOD members to feed him. Not convinced he understands AIM that well either. They will make the calls and it is for that reason why asking Suzy to leave at this moment of time was wrong. You can remove the remaining guys now but again it achieves nothing.
I don't get the point of constantly moaning when changes have been made all at the wrong time.
We should get an update this week. I would imagine we get lots of news all due before any need for further cash.
If the merger completes then 201 should complete. The 201 deal is ongoing so still subject to the merger completing. If it was not they would have had to tell us. Entirely relevant and EUDA are currently worth $47 million based on not much so clearly they are expecting big things shortly which hopefully should reflect on our market cap when completed.
Also if a company is worth 50/60/70 million not only would they likely have cashed raised to complete the merger therefore the deals if they needed to raise an extra million or two to make sure Val was paid then this would be possible without hardly any dilution. I would expect that they have the cash for the trials from TRX for the merger to complete.
The chances still remain good but only time will tell.
For the legal team to accept this is significant and merger should therefore be completed.
Euda Health Adjusts Legal Fees, Issues Shares to CounselCompany Announcements
Euda Health Adjusts Legal Fees, Issues Shares to Counsel
TipRanks Newsdesk
TipRanks Newsdesk
Apr 30, 2024, 10:31 PM
Euda Health Holdings Limited (EUDA) has released an update.
You May Like
Explore attractive offers on the electric Volvo XC40
Volvo Cars
|
Sponsored
Uncovered: People Are Now Ditching Their Glasses for This in April
Lasik Eyes
|
Sponsored
How To Invest In Whisky. Own A Barrel Of Whisky
British Investing
|
Sponsored
Unsold 2024 Bargain Holiday Packages Are Now At Reduced Prices
Favorite Searches
|
Sponsored
Euda Health Holdings Limited has amended its agreement with Loeb & Loeb LLP, increasing the legal fee to $900,000 for services related to a business combination transaction. The fee adjustment includes issuing 60,000 restricted ordinary shares to Loeb and entering into a promissory note for $300,000. This comprehensive legal arrangement covers aspects from fee payment to share transfer regulations, ensuring compliance with U.S. securities laws.
Never a good idea if one is forcing board members to resign only to put himself on the board with no relevant experience. Not sure what everyone is expecting in this situation.
When Stella resigned one should have taken the position and then analysed what was going on. Based on that you would act.
Quick to assume failure. This is drug development not some supermarket where you pick things from the shelf. Trial and testing and timings are often over exaggerated.
Still very much open could go either way but at this market cap only one success is needed for a multi bagger.
I would think SAR is almost certain to be delisted given how low the market cap vs actual spend and requirements for cash.
Valirx has potential with a very modest cash burn. It takes time to find top quality compounds which they have done and now just a bit of work before it is ready for a deal at the preclinical stage. We just need one. CLX is our best hope with the Imperial compound.
The fact the merger work is still ongoing since October then that means it is highly likely to be successful as you don't fail after 6 months of work. If that completes it likely means a much higher market cap and more cash and any rise will be very significant in the medium term.
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
1) You are wrong because I am in no doubt that this Adrian person would help put some incentives for board members with decent targets by June.
2) He was backed by the private shareholder group and others so if he goes in and does a placing at such a crazy price then he has already failed and should be removed immediately as he has no experience in this field and if he goes against what existing shareholders want then it will be curtains for him. I see no reason why the cash burn should increase beyond what has been projected.
The BOD members have not been confirmed yet but I doubt they will be rewarded with very high salaries or that we see more people on the BOD than before.
The projection remains at the end of Q1 2025 and that without any revenue.
Show us the money Porky. Show us the money.
SInce 4D went down I have not seen you ramp a single stock something you would do often in various stocks before 4D day and night. My guess is you simply have nothing left to invest. I find it hard to believe you do not find one stock that is worth posting positively about since 4D collapsed.
Your stock analysis is biased. They have done a great job bringing in top quality projects and having a lab to support it. 201 has been handled poorly but It can still complete soon and hopefully the company will get stronger and stronger after that completes. Not many AIM companies do so much and yet spend only 2 million a year, looking at 4D burning 55 million a year with zero revenue but that was investible to you who was posting his buys on Twitter.
If 201 happens then this should be a 20 bagger in the next 12-18 months when the market improves and hopefully with 1 good preclinical deal and given the quality of the new compounds that is likely.
Calling a 1p placing or no support at all and at 6p which was mainly due to a leak is the same as calling a 30p placing at 6p. Then moving from July to August to September to October to November to December.
What idiot would think that is an accurate prediction.
Borgie,
Looks like you got smashed on BRH and all the other stocks so trying to crossramp here does not work given your track record.
Pure desperation to ask an elderly person to invest in your junk. What a joke.
I was about to post the same. After all these years he is still here with no investment.
No shareholder is going to listen to what you have to say unless you invest first. You have been moving from one thing to another for around 3 years. Very strange indeed to waste time on something he regards as having no value.
So you want 10 evaluations at £100 k a pot then after BOD salary leaves you with zero money to pay for lab staff or to invest in CLX. If there is no lab then you need to pay to outsource the compounds which cost more.
Your finance calculations are as bad as it was when you invested in 4D.
Constantly changing BOD is not going to change the outcomes. The outcomes need to be achieved. Changes only slows things down but then again you are not invested.
My reason for investing in Valirx is purely because of the low risk strategy. No clinical trials and looking for an early deal that would offer significant upfront payment and milestones.
If the strategy changed in the future I would be out. I don't believe that funding clinical trials on AIM would result in a return in investment in most cases especially in a bearish market.